The Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Patients With Treatment Resistant Depression and in Patients With Remitted Bipolar Disorder - a Proof of Concept Study

Trial Profile

The Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Patients With Treatment Resistant Depression and in Patients With Remitted Bipolar Disorder - a Proof of Concept Study

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Bipolar depression; Bipolar disorders
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Actual initiation date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top